How weight-loss jabs could help lower dementia risk
The study also suggests that individuals with type 2 diabetes and obesity prescribed these medications could face a reduced risk of premature death.
Experts from Taiwan conducted a comprehensive study, examining data from 60,000 people worldwide with an average age of 58, all diagnosed with type 2 diabetes and obesity.
During a seven-year follow-up, participants given GLP agonist drugs showed a 37 per cent lower risk of dementia, a 19 per cent reduced risk of stroke, and were 30 per cent less likely to die.
Academics noted potential neuroprotective and cerebrovascular benefits but called for more studies, including randomised clinical trials, to confirm these findings.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
33 minutes ago
- Daily Mail
Lose 5 kilos in 4 weeks with this no-effort method that works for (almost) anyone: You could hardly call it a 'diet' at all - but my clients say it's a game-changer
When Nicole Conville stepped into my clinic, she looked frustrated. At 53, she'd always prided herself on eating a healthy diet and taking daily walks, but when she decided she wanted to lose the few extra kilos that had been bothering her, the scales stubbornly refused to budge.
The Sun
an hour ago
- The Sun
The common conditions that ‘significantly increase your risk of dementia' – and the most dangerous ages to be diagnosed
WHY do some people develop dementia, while others don't? It's a question that's baffled scientists for decades. 2 Some blame booze or obesity, others say it's in your DNA. While there's still no single answer, experts agree it's often triggered by a mix of factors - and one new study reveals that when you get ill could matter just as much as what you get. Getting heart conditions such as heart disease and atrial fibrillation, as well as diabetes, before age 55 could raise your risk of dementia later in life, researchers found. And developing strokes, anxiety or depression between 55 and 70 may double the danger. Experts at the University of Oxford said up to 80 per cent of people with dementia also have two or more other long-term illnesses. But there is still 'a lack of understanding' about how the timing and type of these illnesses affect dementia risk. They identified "critical time windows" in which certain illnesses pose the greatest risk to patients. For the study, published in Brain Communications, experts analysed data from 282,712 people in the UK Biobank and looked at patterns for 46 chronic health problems. Heart issues like atrial fibrillation and diabetes before 55 were most strongly linked to dementia. But from 55 to 70, conditions such as stroke and mental health disorders posed the biggest danger. Five simple tests that could indicate dementia 'Although we knew that multimorbidity increased the risk of dementia, it was unclear which combinations of health conditions had the most impact and in what sequence," Sana Suri, associate professor and senior fellow at Oxford Brain Sciences, said. 'This study has identified how specific illnesses tend to co-exist with each other, and also the critical time windows in which they could pose the greatest risk.' The findings suggest people who get heart disease or diabetes in middle age, followed by mental health issues or stroke later on, are at greatest risk. Sana said these other illnesses should be taken into account when working out someone's likelihood of developing dementia. 'This study identified associations between multimorbidity and dementia risk but we need to understand more about why this happens," she said 'We also need to try to replicate the study in more diverse groups of people to ensure the results are representative of the population." She added: 'Future studies could examine whether efforts to manage or prevent cardiovascular problems in early-to-midlife, followed by mental health and neurological disorders when people are in their fifties and sixties, might reduce the risk of dementia.' 2 A separate study, published earlier this week, suggested two common infections may also play a role in the development of dementia. Researchers from Pennsylvania found both chlamydia pneumoniae and SARS-CoV-2 increase the levels of substances in the brain called cytokines. These trigger inflammation, which can "harm brain cells and may help speed up the buildup of harmful proteins linked to Alzheimer's", the most common form of dementia. Chlamydia pneumoniae is a "very common" type of bacteria that causes lung infections, including pneumonia. It is not the same as the STI chlamydia, though both are highly infectious. SARS-CoV-2 is the virus that causes Covid-19. There are things you can do to reduce your own risk of developing dementia, including Alzheimer's. No single behaviour is guaranteed to prevent dementia - but there's lots of evidence to suggest that making tweaks to your lifestyle choices could affect your risk. Dementia risk is lowest in people who have healthy behaviours in mid-life - from the age of 40 to 65 - according to the Alzheimer's Society. Here are a few easy changes you can make: Exercise regularly to boost your heart health and circulation and help maintain a healthy weight. Drink less alcohol - try to have no more than 14 units of alcohol a week, about one pint of beer or a small glass of wine each day. If you regularly drink much more than this, you are increasing your risk of damage to your brain and other organs, and so increasing your risk of dementia. Don't smoke - it does a lot of harm to the circulation of blood around the body, particularly the blood vessels in the brain, as well as the heart and lungs. Engaging in social activities to help to build up your brain's ability to relieve stress and improve your mood - depression and social isolation have both been linked to dementia. Manage health conditions, such as high blood pressure, high cholesterol or diabetes, which can increase the risk of getting dementia. Protect your eyesight and hearing - vision loss increases a person's risk of developing dementia. The same goes for hearing loss, which can also be an early symptom of dementia. Wear a helmet - as traumatic brain injuries can start a process in the brain where the substances that cause Alzheimer's disease build up around the injured area.
Medical News Today
an hour ago
- Medical News Today
WHO recommends lenacapavir as twice yearly injection to help prevent HIV
The human immunodeficiency virus (HIV), which can lead to acquired immunodeficiency syndrome (AIDS) if not treated, is currently treated by taking antiretroviral there is currently no approved vaccine for HIV. The World Health Organization (WHO) recently issued new guidelines recommending the use of injectable lenacapavir to help prevent HIV. According to UNAIDS, in 2024, about 40.8 million people around the world were living with the human immunodeficiency virus (HIV) — a virus that can lead to acquired immunodeficiency syndrome (AIDS) if not treated. The World Health Organization (WHO) reports that in the same year about 1.3 million people received a new diagnosis of HIV, and about 630,000 died from HIV-related causes. While there is currently no approved vaccine for HIV, the WHO has recently issued new guidelines at the 13th International AIDS Society Conference (IAS 2025) on HIV Science recommending the use of injectable lenacapavir to help prevent infection. What is lenacapavir and how does it work? Lenacapavir is a medication originally designed to treat HIV infection. It is currently sold under the brand names Sunlenca for HIV treatment, and Yeztugo for HIV prevention. According to Carolyn Chu, MD, MSc, FAAFP, AAHIVS, chief medical officer of the American Academy of HIV Medicine, lenacapavir is a novel antiviral medication — belonging to the 'HIV capsid inhibitor' class — which was initially developed for use as part of a combination treatment regimen for people with HIV. 'The initial product (brand name Sunlenca) was approved for treatment in late 2022 based on the CAPELLA Study that examined its safety and efficacy among study participants with HIV who were heavily treatment-experienced and had multidrug-resistant infection,' Chu explained to Medical News Today.'Because of its unique molecular properties, scientists were very interested in determining whether lenacapavir could also be developed for use as an HIV prevention intervention,' she added.'[Lenacapavir] disrupts multiple stages of the HIV life cycle, which makes it an attractive drug to study further — it is also very potent (with effective concentrations at pico-molar ranges) and is active against viruses which may be resistant to HIV medications that have been commonly used over the last decade.'— Carolyn Chu, MDChu said that when lenacapavir was studied as a long-acting pre-exposure prophylaxis (PrEP) HIV preventive option in the PURPOSE clinical trials, investigators found an almost 100% reduction in new HIV infections among participants who received it as a twice-yearly injectable. 'These findings led to its recent approval under a new indication, i.e., used as a prevention medication, brand name Yeztugo,' she added. What are the new WHO lenacapavir guidelines? Through its new guidelines, the WHO recommends the use of injectable lenacapavir twice a year as an additional PrEP option to help prevent HIV. Examples of currently used PrEP options include the oral medications Truvada (emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide), and the injectable drug Apretude (cabotegravir).The WHO also recommended the dapivirine vaginal ring (DVR) in 2021 as an additional PrEP choice for cisgender women. The guidelines are based on safety and efficacy findings for lenacapavir from various studies and clinical trials, most notably PURPOSE 1 and PURPOSE 3 of the PURPOSE 1 trial in cisgender women resulted in no cases of HIV infection among study participants given lenacapavir. Further, the PURPOSE 2 trial found 99.9% of cisgender men and gender-diverse people did not become infected with HIV after receiving the drug. In addition to the lenacapavir recommendation, the WHO also recommends a public health approach to HIV testing through the use of HIV rapid tests. Lenacapavir for people concerned about HIV infectionAccording to the WHO's new guidelines, offering injectable lenacapavir twice a year may help overcome potential barriers to current PrEP options, such as unwillingness to take a regular oral pill and a wish for lower amounts of clinic visits. 'Lenacapavir represents a major scientific advance — it's the first long-acting injectable HIV prevention strategy that requires dosing just twice a year,' Chu told MNT.'For some individuals, especially those who have difficulty adhering to daily or even bimonthly prevention strategies like oral PrEP or cabotegravir, this would be especially welcome,' she Liu, MD, MPH, FACP, FIDSA, chief of infectious diseases at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, explained to MNT that:'Across the world HIV remains a serious disease and preventing new infection is critical. Lenacapavir is an injectable antiviral that lasts 6 months, protecting people for long periods of time. Oral antivirals that are approved for preventing HIV require daily dosing to be effective.' 'People don't like storing oral HIV antivirals at home, where there is stigma attached to those medications, and people forget to take medications or use condoms,' Liu continued. 'Large-scale treatment of people with lenacapavir will be the most efficient way yet to prevent HIV infection until an effective vaccine is produced.'The critical need for HIV prevention HIV and AIDS continue to be a global problem. According to UNAIDS, although the number of new global HIV infections has decreased by about 39% since 2010, there are still areas around the world where numbers are increasing, making the need for HIV prevention critical. 'Prevention of HIV is much less expensive than treating people with HIV infection with expensive antivirals for the rest of their lives,' commented Paul E. Sax, MD, clinical director of the Division of Infectious Diseases at the Brigham and Women's Hospital, and professor of medicine at Harvard Medical is another reason why prevention is important. 'Treatment with antivirals is very difficult to sustain, particularly in poorer countries,' said Sax.'The ideal situation is to have multiple options for preventing HIV among those at risk — this includes not only available PrEP strategies, but also other novel PrEP approaches such as an investigational once-monthly pill for those who don't like or want injections,' he explained.'Of course, we still hope that the HIV vaccine research will advance to the point of giving us an effective vaccine, but the scientific hurdles have proven very high, so we are not anticipating any major breakthroughs in this area in the near future,' Sax added, on a cautionary note. Finally, Chu noted that:'Right now, a lot of conversations are centered on ensuring that everyone who is interested in (lenacapavir) will have access to it. Multiple studies have confirmed that interest in this new option is high, and so our systems and policymakers need to be forward-thinking and work in close collaboration with community members and other stakeholders to ensure that all the necessary pieces to initiate and continue this new PrEP option (e.g., HIV screening/testing, obtaining the medication from pharmacies, training people on how to administer the doses, relaying medication/appointment reminders, etc.) are identified soon and can be rolled out equitably.'
